InflaRx closes $150 million equity offering: 75 million shares at $2 each
InflaRx completed a $150 million underwritten offering of 75 million ordinary shares at $2.00 per share, generating gross proceeds of $150 million before underwriting discounts and expenses. The company plans to use net proceeds to advance its izicopan and vilobelimab pipeline programs, bolster working capital and fund general corporate activities.
1. Offering Details
InflaRx completed an underwritten offering of 75 million ordinary shares at an offering price of $2.00 per share, resulting in gross proceeds of $150 million before deducting the underwriting discount and offering expenses.
2. Use of Proceeds
The company intends to allocate net proceeds to advance its lead programs, izicopan and vilobelimab, while also strengthening working capital and covering general corporate expenses.
3. Underwriting and Participation
The financing saw participation from healthcare funds including TCGX, Farallon Capital, Sirenia Capital, Columbia Threadneedle and others, with Guggenheim Securities serving as lead bookrunner alongside Oppenheimer, LifeSci Capital, Raymond James, Needham and additional co-managers.